Agilent Technologies, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Padraig McDonnell
- Full Time Employees
- 17,900
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 5301 Stevens Creek Boulevard Santa Clara CA United States of America 95051
- IPO Date
- Nov 18, 1999
- CIK
- 0001090872
- Website
- agilent.com
- Similar Companies
- Business
- Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services, and consumables for the life sciences, diagnostics, chemical analysis, and applied markets. The company offers a broad portfolio of products and services including gas chromatography and liquid chromatography systems; mass spectrometry and molecular spectroscopy instruments; microarrays, automation, and informatics solutions; bioreagents, FISH probes, target enrichment, and next-generation sequencing tools; immunohistochemistry and pathology solutions; genomics, proteomics, and cell analysis platforms; sample preparation, GC and HPLC columns, spectrometry supplies, and consumables; as well as laboratory management services encompassing enterprise asset management, compliance support, training, and CrossLab virtual assist for remote technical support. Headquartered in Santa Clara, California, Agilent operates globally in more than 100 countries, serving analytical laboratories, pharmaceutical, biopharma, clinical diagnostics, environmental, forensics, food, energy, academia, and government sectors; it was spun off from Hewlett-Packard in 1999. Recent developments include the completion of its $925 million acquisition of BIOVECTRA, Inc., a Canada-based contract development and manufacturing organization specializing in biologics, active pharmaceutical ingredients, sterile fill-finish, plasmid DNA, mRNA, lipid nanoparticles, antibody-drug conjugates, and high-potency APIs, enhancing Agilent's CDMO capabilities for gene editing and therapeutics; a $7 million investment to modernize R&D and applications labs in Delaware; the launch of the Agilent Innovation Hub in partnership with the University of Melbourne; a strategic collaboration with SeqOne for liquid biopsy data analysis in oncology; and expansions such as a $725 million nucleic acid therapeutics facility in Frederick, Colorado, alongside new product launches driving growth in specialty CDMO services for siRNA and GLP-1 modalities.
Why Is Agilent (A) Up 0.1% Since Last Earnings Report?
Excellere Partners and GHO Capital complete sale of Biocare Medical to Agilent Technologies
Agilent Completes Acquisition of Biocare Medical
Canadian Apartment REIT: A 4.5% Dividend Yield With Ample Coverage
Lost Money on Verra Mobility Corporation (VRRM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
GPK Deadline Alert: Levi & Korsinsky Reminds Graphic Packaging Holding Company (GPK) Investors of Securities Class Action Deadline on July 6, 2026
UMH PROPERTIES, INC. WELCOMES THE 21ST CENTURY ROAD TO HOUSING ACT: A MAJOR BOOST FOR AFFORDABLE MANUFACTURED HOUSING
Tradeweb Announces Date for Second Quarter 2026 Financial Results
The Presidio Group Exclusively Advised Fletcher Jones Automotive Group on the Sale of Porsche, Mercedes-Benz and Audi dealerships in Northern California to AutoNation
MSFT Shareholder Alert: Microsoft Corporation Securities Class Action Lawsuit - Investors Should Contact SueWallSt
Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
Is the Options Market Predicting a Spike in Agilent Technologies Stock?
BALI: A Hidden Covered Call ETF That Could Be Better Than You Think
BLCR: A Top Performing Active Large Cap ETF Worth Watching
SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC
Lost Money on Lucid Group, Inc. (LCID)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
RGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Securities Lawsuit - Contact Levi & Korsinsky
SRAD DEADLINE: Levi & Korsinsky Reminds Sportradar Group AG Investors of Upcoming Securities Class Action Deadline
VDY: A Canadian Yield Compounder, But Not My Top Pick Today